Bismuth quadruple therapy for H. pylori
In a phase 3 trial at 39 European sites, 10-day quadruple therapy (omeprazole plus one capsule of bismuth subcitrate potassium, metronidazole and tetracycline) gave superior H. pylori eradication to 7-day clarithromycin-based triple therapy, with similar safety.
Publisher update notice: erratum
As reported in: Malfertheiner, Bazzoli, Delchier et al. (2011). Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. The Lancet. doi:10.1016/s0140-6736(11)60020-2
Abstract only